XUPB Stock Overview
A late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Genfit S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.34 |
| 52 Week High | €5.45 |
| 52 Week Low | €2.98 |
| Beta | 1.1 |
| 1 Month Change | -13.02% |
| 3 Month Change | -21.96% |
| 1 Year Change | 4.38% |
| 3 Year Change | -28.94% |
| 5 Year Change | n/a |
| Change since IPO | -23.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| XUPB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.3% | -2.9% | -2.6% |
| 1Y | 4.4% | -14.7% | 6.9% |
Return vs Industry: XUPB exceeded the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: XUPB underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| XUPB volatility | |
|---|---|
| XUPB Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XUPB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XUPB's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 169 | M. Prigent | www.genfit.com |
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Genfit S.A. Fundamentals Summary
| XUPB fundamental statistics | |
|---|---|
| Market cap | €172.52m |
| Earnings (TTM) | €22.27m |
| Revenue (TTM) | €80.47m |
7.7x
P/E Ratio2.1x
P/S RatioIs XUPB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XUPB income statement (TTM) | |
|---|---|
| Revenue | €80.47m |
| Cost of Revenue | €0 |
| Gross Profit | €80.47m |
| Other Expenses | €58.20m |
| Earnings | €22.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 100.00% |
| Net Profit Margin | 27.67% |
| Debt/Equity Ratio | 63.9% |
How did XUPB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 20:10 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genfit S.A. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Jean-Jacques Le Fur | Bryan Garnier & Co |
| Arnaud Cadart | CIC Market Solutions (ESN) |